ClinicalTrials.gg
CompletedNCT04224272Updated Sep 24, 2026Results posted

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

A Phase 2 interventional study of ZW25 (Zanidatamab) and Palbociclib in HER2+/HR+ Breast Cancer, sponsored by Jazz Pharmaceuticals. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 286 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Enrollment
643rd of 805
51 · median 151
Started
2020
with 58 others
Phase 2
248 of 905
21 open now
Registered
548th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 643rd largest by enrollment of the 805 interventional ones that give a count, is one of 59 that started in 2020, is one of 248 in phase 2, and was the 548th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in combination with palbociclib plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.

Read the detailed description

Part 1 of the study will first evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant and will confirm the recommended doses (RDs) of ZW25 and palbociclib in this combination. Part 2 of the study will evaluate the anti-tumor activity of the combination of ZW25 with palbociclib plus fulvestrant at the RD level in patients with HER2-positive, HR-positive advanced breast cancer.

03

Conditions studied

  • HER2+/HR+ Breast Cancer

Browse trials for

Keywords

  • HER2
  • HR
  • Bispecific antibody
  • Biparatopic antibody
  • Immunotherapy
  • Breast cancer
  • Chemotherapy
  • Palbociclib
  • Fulvestrant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed diagnosis of breast cancer with evidence of locally advanced (unresectable) and/or disease. All patients in both Parts 1 and 2 must have -positive and HR-positive disease.
  • Received prior treatment with trastuzumab, pertuzumab, AND ado-trastuzumab emtansine (T-DM1); disease progression during or after the most recent prior therapy. Patients in any part of the study who did not receive pertuzumab or T-DM1 because of lack of access (e.g., due to insurance coverage or because they were treated prior to regulatory agency approval of the agent in a relevant indication) or due to medical ineligibility for treatment with T-DM1 (e.g., history of severe infusion reactions to trastuzumab, >/= Grade 2 peripheral neuropathy, or count \< 100 x 10\^9/L) may be eligible for the study. Prior treatment with endocrine therapy in the , adjuvant, and/or metastatic setting is permitted.
  • Sites of disease assessible per version 1.1 (both measurable and non- allowed)
  • An (ECOG) Performance Status score of 0 or 1
  • Adequate organ function
  • Adequate cardiac left ventricular function, as defined by (LVEF) >/= institutional standard of normal

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with trastuzumab, pertuzumab, lapatinib, T-DM1, or other anti--targeted therapy \</= 3 weeks before the first dose of ZW25
  • Prior treatment with chemotherapy, other anti-cancer therapy not otherwise specified, or hormonal cancer therapy \</= 3 weeks before the first dose of ZW25
  • Prior treatment with palbociclib or any other CDK4/6 inhibitor, including experimental agents
  • History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure (CHF)
  • Fridericia (QTcF) > 470 ms
  • Grade 2 or greater pneumonitis and/or interstitial lung disease, including pulmonary fibrosis, or other clinically significant infiltrative pulmonary disease not related to lung
  • Active or infection
  • Acute or chronic uncontrolled renal disease, pancreatitis, or severe liver disease ( Class C)
  • Known infection with (HIV)-1 or HIV-2 (Exception: patients with well controlled-HIV [e.g., cluster of differentiation 4 (CD4)-positive T-cell count > 350 mm3 and undetectable viral load] are eligible.)
  • Prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the regimen
  • : Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as patients who are off and anticonvulsants and are neurologically stable for at least 1 month at the time of screening).
  • History of or ongoing
  • Grade 3 or greater peripheral neuropathy
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    ZW25 (zanidatamab) + palbociclib + fulvestrant

    Participants who received intravenous dose of 20 mg/kg ZW25 (zanidatamab) every 2 weeks (Q2W) in combination with an oral administration of 125 mg palbociclib once daily from Days 1 to 21, and an intramuscular injection of 500 mg fulvestrant Q2W for 3 doses (Cycle 1 Days 1 and 15 and Cycle 2 Day 1), and every 4 weeks (Q4W) thereafter.

    Drug: ZW25 (Zanidatamab) · Drug: Palbociclib · Drug: Fulvestrant

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities

    Dose-limiting toxicities, defined using NCI CTCAE version 5.0, are events that 1) occur following administration of ZW25, palbociclib, and fulvestrant; and 2) meet the criteria as specified in the protocol.

    Time frame: Cycle 1 Day 1 to Day 28 (each cycle is 28 days)

  2. Number of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events

    A treatment-emergent adverse event occurs after the start of study treatment and is defined as any unfavorable or unintended symptom, sign, or disease (including abnormal lab) temporally associated with the use of treatment that may or may not be considered related to treatment. TEAEs were coded using MedDRA v24.0.

    Time frame: From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.

  3. Progression-free Survival 6

    The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days).

    Time frame: 6 months from first dose of all study drugs to the date of documented disease progression or death

Secondary outcomes

  1. Number of Participants Reporting Any Treatment-emergent Adverse Event, Serious Adverse Event, and Adverse Event of Special Interest

    A treatment-emergent adverse events (TEAEs) was defined as an adverse event (AE) with onset on or after 1st dose of study treatment through 30 days after final dose of study treatment inclusive. An AE is classified as a serious adverse event (SAE) if fatal, life threatening, requires hospitalization, is disabling/incapacitating, causes congenital anomaly or birth defect, and medically significant. Adverse events of special interest (AESI) include absolute decrease in LVEF greater than or equal to 10 percentage points from baseline and LVEF value less than 50% post-baseline or LVEF value greater than or equal to 20% to less than or equal to 39% post baseline, symptomatic heart failure, infusion-related reactions, and all greater than or equal to Grade 2 events of pneumonitis and/or interstitial lung disease, including pulmonary fibrosis.

    Time frame: From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days

  2. Maximum Serum Concentration Steady State of ZW25

    Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA).

    Time frame: End of ZW25 infusion on Cycle 4 Day 1 (steady state) (each cycle is 28 days)

  3. Trough Concentration Steady State of ZW25

    Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA).

    Time frame: Predose at Cycle 4 Day 1 (steady state) (each cycle is 28 days)

  4. Number of Participants With Anti-drug Antibodies (ADAs) Post-baseline

    Participants were considered to be ADA positive if they were initially ADA negative at baseline and tested positive for ADAs following study drug exposure ("treatment-induced ADA response"), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater than the titer of the baseline sample ("treatment-enhanced ADA response"). Participants were considered to be ADA negative if they were ADA negative at baseline and all post-baseline samples were negative, or if they were ADA positive at baseline but did not have any post-baseline samples with a titer that was at least 4-fold greater than the titer of the baseline sample ("treatment-unaffected ADA").

    Time frame: Predose at Cycle 1 Days 1 and 15; Cycle 2 Days 1 and 15; Cycle 4 Day 1 and subsequent ADA assessment visits; end of treatment; 30 days post last dose (safety FU); and every 8 weeks (efficacy FU) (each cycle, 28 days), up to approximately 5 years 20 days.

  5. Objective Response Rate

    Confirmed objective response rate is defined as the number of patients with confirmed complete response (CR) and confirmed partial response (PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions as assessed by the Investigator per RECIST v1.1.

    Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days

  6. Duration of Response

    DOR is defined as the time from the first confirmed objective response (CR or PR) to documented PD per RECIST 1.1 or death within 30 days of last dose of study drug (ZW25, palbociclib, and/or fulvestrant) from any cause. Only participants who achieved a confirmed objective response were included in the analysis.

    Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days

  7. Disease Control Rate

    Disease control is defined as a best response of CR, PR, non-CR/non-PD (for participants who have only non-target lesions), or SD per RECIST 1.1. The proportion of participants who achieve a disease control response was calculated.

    Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days

  8. Progression-free Survival

    Progression-free survival (PFS) time is defined as the time from first dose of ZW25, palbociclib, and/or fulvestrant to the date of first documented disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.

    Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days

  9. Overall Survival

    OS is defined as time from first dose of ZW25, palbociclib, and/or fulvestrant until death from any cause.

    Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days

  10. Incidence of Abnormal Hepatic Lab Values

    Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days

07

Results

Posted Aug 14, 2024

Participant flow

A total of 51 participants who met all eligibility criteria were enrolled and received treatment. This study was officially completed on 30 June 2025. All efficacy and safety analyses were conducted as planned.

Part 1 - Dose Finding
Participant flow — Part 1 - Dose Finding
MilestoneZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Started8
Completed0
Not completed8
Withdrew: Death5
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up1
Part 2 - Dose Expansion
Participant flow — Part 2 - Dose Expansion
MilestoneZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Started43
Completed0
Not completed43
Withdrew: Death22
Withdrew: Withdrawal by subject5
Withdrew: Sponsor decision16

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities

Dose-limiting toxicities, defined using NCI CTCAE version 5.0, are events that 1) occur following administration of ZW25, palbociclib, and fulvestrant; and 2) meet the criteria as specified in the protocol.

Time frame:
Cycle 1 Day 1 to Day 28 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities
ParticipantsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Number of Participants With Dose-Limiting Toxicities1
PrimaryNumber of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events

A treatment-emergent adverse event occurs after the start of study treatment and is defined as any unfavorable or unintended symptom, sign, or disease (including abnormal lab) temporally associated with the use of treatment that may or may not be considered related to treatment. TEAEs were coded using MedDRA v24.0.

Time frame:
From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.
Reported as:
Count of participants · Participants
Number of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events
ParticipantsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Any Blood and Lymphatic System Disorders AE20
Neutropenia16
Anaemia6
Thrombocytopenia3
Leukopenia1
Any Gastrointestinal Disorder AE13
Diarrhoea8
Abdominal pain1
Duodenal ulcer1
Gastric ulcer1
Nausea1
Small intestinal obstruction1
Stomatitis1
Vomiting1
Any Investigation AE12
Neutrophil count decreased11
Ejection fraction decreased1
Transaminases increased1
White blood cell count decreased2
Any Metabolism and Nutrition Disorder AE8
Hypokalaemia4
Hypomagnesaemia3
Hypercalcaemia2
Any General Disorders and Administration Site Conditions AE2
Fatigue1
Pyrexia1
Asthenia1
Any Infections and Infestations AE2
COVID-19 pneumonia1
Psoas abscess1
Staphylococcal bacteraemia1
Cellulitis1
Any Respiratory, Thoracic and Mediastinal Disorder AE2
Pleural effusion1
Pneumothorax1
Pulmonary embolism1
Any Renal and Urinary Disorder AE1
Acute kidney injury1
Any Skin and Subcutaneous Tissue Disorder AE1
Rash maculo-papular1
PrimaryProgression-free Survival 6

The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days).

Time frame:
6 months from first dose of all study drugs to the date of documented disease progression or death
Reported as:
Count of participants · Participants
Progression-free Survival 6
ParticipantsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Progression-free Survival 634
SecondaryNumber of Participants Reporting Any Treatment-emergent Adverse Event, Serious Adverse Event, and Adverse Event of Special Interest

A treatment-emergent adverse events (TEAEs) was defined as an adverse event (AE) with onset on or after 1st dose of study treatment through 30 days after final dose of study treatment inclusive. An AE is classified as a serious adverse event (SAE) if fatal, life threatening, requires hospitalization, is disabling/incapacitating, causes congenital anomaly or birth defect, and medically significant. Adverse events of special interest (AESI) include absolute decrease in LVEF greater than or equal to 10 percentage points from baseline and LVEF value less than 50% post-baseline or LVEF value greater than or equal to 20% to less than or equal to 39% post baseline, symptomatic heart failure, infusion-related reactions, and all greater than or equal to Grade 2 events of pneumonitis and/or interstitial lung disease, including pulmonary fibrosis.

Time frame:
From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Treatment-emergent Adverse Event, Serious Adverse Event, and Adverse Event of Special Interest
ParticipantsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
TEAE51
Grade 3 or higher TEAEs39
SAE9
AESI5
SecondaryMaximum Serum Concentration Steady State of ZW25

Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA).

Time frame:
End of ZW25 infusion on Cycle 4 Day 1 (steady state) (each cycle is 28 days)
Reported as:
Mean · ug/mL
Maximum Serum Concentration Steady State of ZW25
ug/mLZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Maximum Serum Concentration Steady State of ZW25726.80 ± 147.66
SecondaryTrough Concentration Steady State of ZW25

Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA).

Time frame:
Predose at Cycle 4 Day 1 (steady state) (each cycle is 28 days)
Reported as:
Mean · ug/mL
Trough Concentration Steady State of ZW25
ug/mLZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Trough Concentration Steady State of ZW25253.47 ± 54.0
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) Post-baseline

Participants were considered to be ADA positive if they were initially ADA negative at baseline and tested positive for ADAs following study drug exposure ("treatment-induced ADA response"), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater than the titer of the baseline sample ("treatment-enhanced ADA response"). Participants were considered to be ADA negative if they were ADA negative at baseline and all post-baseline samples were negative, or if they were ADA positive at baseline but did not have any post-baseline samples with a titer that was at least 4-fold greater than the titer of the baseline sample ("treatment-unaffected ADA").

Time frame:
Predose at Cycle 1 Days 1 and 15; Cycle 2 Days 1 and 15; Cycle 4 Day 1 and subsequent ADA assessment visits; end of treatment; 30 days post last dose (safety FU); and every 8 weeks (efficacy FU) (each cycle, 28 days), up to approximately 5 years 20 days.
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) Post-baseline
ParticipantsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Number of patients positive for treatment-emergent ADA10
Number of patients negative for treatment-emergent ADA37
SecondaryObjective Response Rate

Confirmed objective response rate is defined as the number of patients with confirmed complete response (CR) and confirmed partial response (PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions as assessed by the Investigator per RECIST v1.1.

Time frame:
From first dose of treatment up to end of study, approximately 5 years 20 days
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Objective Response Rate16
SecondaryDuration of Response

DOR is defined as the time from the first confirmed objective response (CR or PR) to documented PD per RECIST 1.1 or death within 30 days of last dose of study drug (ZW25, palbociclib, and/or fulvestrant) from any cause. Only participants who achieved a confirmed objective response were included in the analysis.

Time frame:
From first dose of treatment up to end of study, approximately 5 years 20 days
Reported as:
Median · months
Duration of Response
monthsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Duration of Response13.16 (9.20 to 22.34)
SecondaryDisease Control Rate

Disease control is defined as a best response of CR, PR, non-CR/non-PD (for participants who have only non-target lesions), or SD per RECIST 1.1. The proportion of participants who achieve a disease control response was calculated.

Time frame:
From first dose of treatment up to end of study, approximately 5 years 20 days
Reported as:
Count of participants · Participants
Disease Control Rate
ParticipantsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Disease Control Rate42
SecondaryProgression-free Survival

Progression-free survival (PFS) time is defined as the time from first dose of ZW25, palbociclib, and/or fulvestrant to the date of first documented disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.

Time frame:
From first dose of treatment up to end of study, approximately 5 years 20 days
Reported as:
Median · months
Progression-free Survival
monthsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Progression-free Survival9.30 (8.38 to 14.42)
SecondaryOverall Survival

OS is defined as time from first dose of ZW25, palbociclib, and/or fulvestrant until death from any cause.

Time frame:
From first dose of treatment up to end of study, approximately 5 years 20 days
Reported as:
Median · months
Overall Survival
monthsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Overall Survival32.20 (24.18 to NA)
SecondaryIncidence of Abnormal Hepatic Lab Values
Time frame:
From first dose of treatment up to end of study, approximately 5 years 20 days
Reported as:
Count of participants · Participants
Incidence of Abnormal Hepatic Lab Values
ParticipantsZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Participants with ALT > 5 x ULN1
Participants with AST > 5 x ULN2
Participants with AST or ALT > 3 x ULN and ≤ 5 x ULN4
Participants with ALP > 2 x ULN10
Participants with total bilirubin > 2 x ULN1
Patients w/ potential Drug Induced Liver Injury: AST or ALT > 3 x ULN & total bilirubin > 2 x ULN1
Patients w/ potential Hy's law: AST or ALT > 3 x ULN & total bilirubin > 2 x ULN and ALP < 2 x ULN0

Adverse events

Collected over Adverse events were collected from the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZW25 (Zanidatamab) + Palbociclib + Fulvestrant27/51 (52.9%)9/51 (17.6%)51/51 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Duodenal ulcerGastrointestinal disorders1/51
Gastric ulcerGastrointestinal disorders1/51
Small intestinal obstructionGastrointestinal disorders1/51
COVID-19Infections and infestations1/51
COVID-19 pneumoniaInfections and infestations1/51
Psoas abscessInfections and infestations1/51
Staphylococcal bacteraemiaInfections and infestations1/51
Pleural effusionRespiratory, thoracic and mediastinal disorders1/51
PneumothoraxRespiratory, thoracic and mediastinal disorders1/51
AnaemiaBlood and lymphatic system disorders1/51
Most frequent other events
Showing 10 of 51
Most frequent other events
EventZW25 (Zanidatamab) + Palbociclib + Fulvestrant
DiarrhoeaGastrointestinal disorders47/51
NauseaGastrointestinal disorders29/51
StomatitisGastrointestinal disorders21/51
AstheniaGeneral disorders19/51
NeutropeniaBlood and lymphatic system disorders19/51
VomitingGastrointestinal disorders18/51
AnaemiaBlood and lymphatic system disorders16/51
Neutrophil count decreasedInvestigations14/51
Decreased appetiteMetabolism and nutrition disorders12/51
Abdominal painGastrointestinal disorders11/51

Baseline characteristics

The baseline demographic characteristics were assessed in the Safety Analysis Set.

Age, Continuous
Age, Continuous(years)ZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Mean54.7 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)ZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Female49
Male2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Asian2
Black or African American1
White42
Multiple1
Other1
Unknown3
Not Reported1
08

Study locations

13 sites
  • UCLA Hematology/Oncology Parkside
    Santa Monica, California 90404, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N4N2, Canada
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Research Institute
    Toronto, Ontario M4N3M5, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T1E2, Canada
  • Hospital General Universitario de Elche
    Elche, Alicante 03203, Spain
  • Hospital Universitario Vall d'Hebrón
    Barcelona, 08035, Spain
  • Hospital Ruber Internacional
    Madrid, 28034, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, 41013, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
09

References and documents

Publications

  • Escriva-de-Romani S, Cejalvo JM, Alba E, Friedmann J, Rodriguez-Lescure A, Savard MF, Pezo RC, Gion M, Ruiz-Borrego M, Hamilton E, Pluard T, Webster M, Beeram M, Linden H, Saura C, Shpektor D, Salim B, Harvey P, Hurvitz SA. Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. Lancet Oncol. 2025 Jun;26(6):745-758. doi: 10.1016/S1470-2045(25)00140-8. Epub 2025 May 5. PubMed 40339592 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Apr 2023, 34 months.

Results were first posted in Aug 2024, 1 year 3 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 34 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Jan 13, 2020
StartActual
Jun 10, 2020
Primary completionActual
Apr 28, 2023
CompletionActual
Jun 30, 2025
Results first posted
Aug 14, 2024
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04224272
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Jun 10, 2020
Primary completion
Apr 28, 2023
Completion
Jun 30, 2025
Results posted
Aug 14, 2024
Last update
Sep 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanidatamab

Start the discussion